Sign in Subscribe
Liver diseases

Real-World Work Productivity Impaired in People with Metabolic Dysfunction-Associated Steatotic Liver Disease

Strategic Insights

— 1 min read

Recent research has shed light on the impact of metabolic dysfunction-associated steatohepatitis (MASH) on patient-reported outcomes, specifically work productivity. A study published in the journal JHEP Reports found that work productivity is impaired in people with MASH, with a significant difference in activity impairment scores between high-risk and low-risk patients. The study analyzed data from the Adelphi Real World MASH Disease Specific Programmes in the USA, which included cross-sectional surveys of physicians and patients in 2019 and 2022.

Key Takeaways:

  • The study assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities).
  • Physicians reported sociodemographic data and signs/symptoms for eight or fewer consecutive participants with MASH, while participants voluntarily completed questionnaires assessing work productivity, health status, and quality of life/symptoms.
  • In total, 87 physicians and 429 individuals with MASH provided data, with activity impairment scores significantly higher in high-risk (30.8%) compared to low-risk (17%) individuals.
  • Principal components factor analysis identified factors from MASH signs and symptoms, while elastic net regression determined features associated with work productivity impairment.
  • The study concluded that general, non-specific signs could represent possible early warning signs preceding reduced productivity in patients with MASH.
  • The research highlights the need for early identification and intervention to prevent work productivity impairment in people with MASH.

Statistics:

  • 87 physicians and 429 individuals with MASH provided data for the study.
  • Activity impairment scores were significantly higher in high-risk (30.8%) compared to low-risk (17%) individuals with MASH.
  • Principal components factor analysis identified 10 factors representing MASH signs and symptoms.
  • Elastic net regression determined 5 features associated with work productivity impairment.
  • The study analyzed data from the Adelphi Real World MASH Disease Specific Programmes in the USA, including cross-sectional surveys of physicians and patients in 2019 and 2022.

Sources:

  • Real-world work productivity is impaired in people with metabolic dysfunction-associated steatotic liver disease in the USA. JHEP Reports, 2025;7(11):101558.
  • The publisher of the journal JHEP Reports: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
  • NewsRx. New Liver Diseases and Conditions Findings from University of Chicago Reported (Real-world work productivity is impaired in people with metabolic dysfunction-associated steatotic liver disease in the USA). Health & Medicine Week. October 31, 2025; p 3701.

Read more